Pacific Edge today announces its key activities at the 2023 AUA Annual meeting to be held April 28 – May 1 in Chicago, Illinois.
The AUA annual meeting, now in its 118th year, is the largest and most prestigious event on the US and global urological calendar, attracting thousands of urologists, uro-oncologists, researchers, educators, advanced practice providers, and other healthcare professionals from around the world.
Pacific Edge will expand its presence at the AUA this year, anchored by a booth in the main hall through which the team will update customers and attendees on the latest product, industry, and clinical program developments. Over the course of the event, we’ll also be coordinating a range of activities designed to connect with clinicians, key opinion leaders (KOLs), and research partners.
Pacific Edge will sponsor several sessions on Sunday April 30, including a breakfast for the Society of Women in Urology; a meeting of the Urological Society for American Veterans (USAV) – the VA is a major partner in our clinical evidence generation program and the largest health system in the USA; and a Bladder Cancer Forum hosted by the International Bladder Cancer Group (IBCG). The forum, initiated at AUA 2022, is now an important platform for thought leadership within the AUA, and will feature expert panelists from around the world leading practical, case-based debates that address common problems and dilemmas in the management of bladder cancer. This year the forum will be moderated by Dr. Ashish Kamat and Dr. Roger Li.
Further detail on the sponsored Sunday sessions:
- 7:30am – 10am Society of Women in Urology (SWIU) Annual Breakfast (Jackson Park Room, Hyatt Regency McCormick Place)
- 10:30am – 2:30pm Urological Society for American Veterans (USAV) (Regency Ballroom CDE, Hyatt Regency McCormick Place)
- 2pm – 5pm Bladder Cancer Forum (Vista Room, McCormick Place Convention Center)
Pacific Edge will also sponsor a continuing medical education (CME) course, 8am Friday, April 28 at the Convention Center, focused on the treatment and care of patients with non-muscle invasive bladder cancer (NMIBC) during a shortage of BCG, an immunotherapy drug used in the treatment of early-stage bladder cancer.
Pacific Edge’s CEO, Dr. Peter Meintjes says: “Events like AUA provide Pacific Edge the best opportunity to listen to the needs of key opinion leaders and currently practicing urologists in relation to future partnership and product developments for Cxbladder. Reciprocally, it is also our best opportunity to educate the urology community on what has already been achieved with Cxbladder by our clinical trials partners, research collaborators, high-throughput users and advocates. I am delighted by the program we’ve put together and look forward to connecting with as many customers and partners as possible.”